Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risk biomarkers in Spanish AIDS R&D (research and development) funding :

This article was originally published in Clinica

Executive Summary

Research into biomarkers for assessing the risk of pre-eclampsia and intrauterine foetal death in HIV-infected women is the theme of one of the 22 projects that have been approved for funding under Spain's AIDS research and prevention foundation (FIPSE). Markers for cardiovascular risk as predictors of atherosclerosis linked to HIV infection will also get a share of this year's Euro2.04m ($2.4m) fund. Others include research into the HIV transcription factor CA-150 and monitoring the response of HIV-infected women to anti-retrovirals during pregnancy. This sixth funding round brings FIPSE's total disbursement to date to Euro13.6m, among 149 projects.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057967

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel